Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.

  • News

Executive Summary

Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.

You may also be interested in...



Novartis Reduces Outsourcing Through Parexel; CRO To Lay Off 400-500

Novartis' cancellation of several outsourcing contracts with Parexel could result in a reduction of the contract research organization's workforce by 400-500 positions, Parexel said.

Amgen Is Biotech Again; Genomic Data Drives Sector To New Highs

Amgen is reclaiming its biotech identity as Wall Street rushes back to biotechnology.

Abgenix Run-Up In Value Ends Cell Genesys/Genzyme Merger

Cell Genesys spin-off Abgenix' success in marketing its XenoMouse technology has helped terminate a proposed merger between Genzyme and Cell Genesys.

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS035712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By